Compositions for use to treat advanced glycation end products-dependent ocular diseases

The present invention relates to the treatment of blindness due to age-related presbyopia, age- related macular degeneration (AMD), diabetic retinopathy (DR) and/or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons >65 years in the western world. At the time being no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drusen, which are (sub)retinal accumulations of advanced glycation end products (AGEs) and fluorophores. DR and DME are the most common cause of irreversible loss of sight in persons <65 years in the western world. Current therapies for age-related presbyopia, AMD, DR and DME are disappointing and do not prevent the evolution to vision impairment, atrophy or blindness. The invention specifically relates to the administration of fructosamine-3-kinase and its cofactor(s). This results in deglycation and inactivation of AGEs and fluorophores.

Patent Publication Number: WO2020053188

Year filing: 2020

Year approval: 2021

Year publication: 2020

Status: Requested

Technology domains: Pharmaceuticals

Validated for IOF-key: Yes

Attributed to: Associatie Universiteit Gent